By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Chemin des Aulx, 12
1228 Plan-les-Ouates
  Geneva    Switzerland
Phone: n/a Fax: n/a


Company News
ObsEva (OBSV) Announces The Completion Of A Phase I Drug-Drug Interaction Study With OBE022 5/18/2017 10:44:37 AM
ObsEva (OBSV) Reports First Quarter 2017 Financial Results and Business Update 5/18/2017 10:42:10 AM
ObsEva (OBSV) To Hold First Quarter 2017 Financial Results And Business Update Call On Thursday, May 18, 2017 5/11/2017 11:14:42 AM
ObsEva (OBSV) Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids 4/25/2017 9:57:20 AM
ObsEva (OBSV) To Present Pharmacology Results Demonstrating OBE022 Exerts A Synergistic Effect In Combination With Standard Of Care In Animal Model For Preterm Labor 3/17/2017 10:56:27 AM
ObsEva (OBSV) Starts Phase III Clinical Program For Nolasiban In ART 3/7/2017 8:59:06 AM
Women's Health Biotech ObsEva (OBSV) to Open Up U.S. HQ in Boston After $97 Million IPO 1/30/2017 5:49:17 AM
ObsEva (OBSV) Release: Pharma To Ring The Nasdaq Stock Market Opening Bell In Celebration Of Its IPO 1/26/2017 7:43:17 AM
ObsEva (OBSV) Release: Pharma Announces Pricing Of Initial Public Offering 1/26/2017 7:42:03 AM
ObsEva Release: Company Expands Leadership Team And Board Of Directors With Industry Veterans 1/17/2017 7:15:38 AM